Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-0524B versus atorvastatin in adults with mixed hyperlipidemia
2007-000037-19Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Niacin + laropiprant + simvastatin and atorvastatin in combined dyslipidaemia (8 arms), sponsored by Merck & Co. Primary endpoint: Percent change from baseline in LDL-C/HDL-C ratio at 12 weeks. Started Jun 2008; status: completed.
02
Drugs
Niacin + laropiprant + simvastatinatorvastatin
03
Conditions
combined dyslipidaemia
Beyond the preview
Go deeper on 2007-000037-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000037-19.